Our Plan

WHERE TO BUY
Brands
EN
Current location and language options: (EN)
EN
Current location and language options: (EN)
Brands
Ego’s Eczema Management Action Plan

First-line management common to all severities of eczema includes the use of short-term topical corticosteroids to control flare ups1, combined with the long-term use of moisturisers or emollients to relieve symptoms and maintain the skin barrier2.

Research has shown that together,

we can achieve a 50% reduction in eczema severity

and better clinical outcomes for your patients when topical corticosteroids and emollients are used in combination to manage eczema3. By adding an emollient to active treatment, eczema severity is reduced and may led to fewer flares3.

5 Steps To Every Plan

Guidelines recommend a stepped approach for managing atopic eczema2. Before recommending a management plan for your eczema patient, it’s important to first evaluate the severity of the eczema and needs of the patient to determine the appropriate stepped approach to treatment.

ACCESS THE PLAN
Our Featured Products

PBS Information: Zatamil Lotion and Zatamil Ointment 15g: Restricted benefits. Corticosteroid-responsive dermatoses. Zatamil Lotion and Zatamil Ointment 15g: Authority required (Streamlined). Refer to PBS Schedule for full authority information. Zatamil Hydrogel and Zatamil Ointment 45g: These are not listed on the PBS.

Before prescribing or recommending DermAid, Kloxema or Zatamil please review the full Product Information. Full Product Information is available on request from Ego Pharmaceuticals Pty Ltd and can be accessed at ebs.tga.gov.au.

Zatamil (mometasone furoate) ointment: Short term (up to four continuous weeks) relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, such as psoriasis and atopic dermatitis. Contraindications: Hypersensitivity to mometasone furoate or to other corticosteroids. Viral infections of the skin, tuberculosis, acne rosacea, perioral dermatitis, fungal skin infections and ulcerative conditions. Precautions: Irritation or sensitisation; infection; infants and children; prolonged or extensive use; occlusion; eye contact; pregnancy (Category B3); lactation. Adverse Reactions: Itching; burning; stinging; skin atrophy; acneiform reactions. Dosage and Administration: Apply a thin film of zatamil ointment to the affected skin area once daily. Kloxema (clobetasone butyrate): Short term (up to 7 days) treatment of milder forms of eczema, dermatitis and other steroid responsive skin conditions. Dosage: For 12 years and over. Apply a thin film and gently rub in, using only enough to cover the affected area twice daily for up to 7 days. Contraindications: Kloxema cream should not be used in patients with a history of hypersensitivity to clobetasone butyrate or to any of the excipients in the product. Rosacea, acne, pruritis without rash, perioral dermatitis; Untreated bacterial infections such as cellulitis, folliculitis, furunculosis or impetigo; Fungal infections such as those associated with tinea (eg athlete’s foot, jock itch); Viral infections including cold sores (herpes simplex), chicken pox or shingles (Varicella zoster) or vaccinia; Parasitic infestations such as scabies. Do not use on broken or infected skin or on inflamed skin near chronic ulcers. DermAid (hydrocortisone): For the temporary relief of symptoms associated with acute and chronic corticosteroid responsive conditions including: minor skin irritations, itching and rashes due to eczema, dermatitis, contact dermatitis (such as rashes due to cosmetics and jewellery), psoriasis, anogenital pruritus and sunburn. DermAid 1% cream: Apply a thin layer to affected skin 1–2 times daily as required. Contraindications: vaccinia, chicken pox, herpes and other viral infections, bacterial infections, tuberculosis of the skin and syphilitic skin disorders. Hypersensitivity to hydrocortisone, other corticosteroids or any other ingredient in the product. Do not use in the eye. QV Dermcare Eczema Daily Wash and Daily Cream: Help relieve the symptoms of mild to moderate eczema.

References

1. Smith S, Baker C, Gebauer K, Rubel D, Franum B, Soyer HP, et al. Atopic Dermatitis in adults: An Australian management consensus. Australasian Journal of Dermatology 2020;61(1):23-32.

2. National Institute for Health and Care Excellence. Atopic eczema in under 12s: diagnosis and management Available at: https://www.nice.org.uk/guidance/cg57/ resources/atopic-eczema-in-under12s-diagnosis-andmanagement-pdf-975512529349 (accessed Dec 2022).

3. Van Zuuren EJ, Fedorowicz Z, Christensen R, Lavrijsen APM, Arents BWM (2017) Emollients and moisturisers for eczema. Cochrane Database of Systematic Reviews 2017, Issue 2. Art. No.: CD012119. DOI: 10.1002/14651858. CD012119.pub2.

4. Kantar Health. Mini Health professional poll. 2017. Australia. (n=15). Sponsored by Ego Pharmaceuticals Pty Ltd. Result based ‘Level of involvement of HCPs during patient journey.’